NEW YORK (GenomeWeb News) – Physician's Choice Laboratory Services today announced a partnership to offer Genesys Biolabs' proteomic test for screening and the early detection of lung cancer.
The test, called PAULA's Test, short for Protein Assay Using Lung Cancer Analytes, measures three tumor proteins and an additional analyte that are commonly associated with lung cancer. The blood-based test is analyzed in Genesys' CLIA-certified laboratory.
Citing statistics from the American Cancer Society, PCLS said that about 228,190 new cases of lung cancer will be diagnosed this year in the US with 159,480 lung cancer-associated deaths.
PCLS, based in Rock Hill, SC, provides toxicology and genetics testing services. Genesys is a division of 20/20 GeneSystems and develops proteomic-based diagnostics tests with a focus on cancer. It is headquartered in Rockville, Md.
Financial and other terms of the agreement were not disclosed.